Type 2 Diabetes

Key opinion leaders in endocrinology provide an overview of factors to consider when selecting or switching intranasal and injectable glucagon including ease of administration and patient preference.

Thought leaders in diabetes discuss challenges of insurance coverage for new formulations of glucagon and comment on the potential for long-term cost savings due to decreased overall healthcare system utilization.

Data show SGLT2is reduced HHF in patients with both stablished HFrEF and CKD and are likely to also be effective in patients with HFpEF.

With approval on July 9, finerenone (Kerendia) becomes the first nonsteroidal mineralocorticoid receptor antagonist to receive approval for use in adults with chronic kidney disease associated with type 2 diabetes.

Diana Isaacs, PharmD, offers perspective on her top 5 CGM-related studies or presentations from the American Diabetes Association's 81st Scientific Sessions.

FDA cites pharmacokinetic comparability considerations remained outstanding, while no clinical deficiencies on efficacy and safety were reported.

Despite having a favorable vote in a recent FDA AdComm meeting, Provention Bio announced the FDA has issued a CRL for teplizumab for the delay of type 1 diabetes in at-risk individuals.

Insights from the DISCOVER registry were presented at the American Diabetes Association's 81st Scientific Sessions. Check out our Q&A with study presenter Suzanne Arnold, MD, of St. Luke's Mid America Heart Institute.

Marc Bonaca, MD, discusses a new analysis of the VOYAGER PAD trial and implications for patients with diabetes and CLI.

Dennis Bruemmer, MD discusses new agents and perspectives on care in treating patients with type 2 diabetes at high risk of CV, renal complications.

Investigators say that dietary habits in youth and young adult patients with diabetes can be impacted by income, employment, ethnicity, and a variety of other factors.

Elaine M. Apperson discusses treating diabetes in a pediatric population, including diabetes burnout, the effects of food deserts, and the consequences of COVID-19 on treatment.

Data show event rates varied two-fold across regions, with risk reduction of T2D and CKD events across geographic regions without heterogeneity.

Our editorial staff has selected a shortlist of highlighted data and summary slides on their picks of the most important data to be released at the American Diabetes Association's 81st Annual Scientific Sessions.

Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.

Researchers push for transparency between health care professionals and patients with diabetes about the safety and efficacy of the influenza vaccine

In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.

Data from the SURPASS program presented at ADA 2021 provide insight into the effects of tirzepatide on HbA1c control and body weight in a variety of different patient populations as both an add-on and monotherapy.

Investigative ORMD-0701 has potential to regulate the insulin-glucagon balance in patients.

While still waiting for regulatory approval, the SCORED and SOLOIST trial have demonstrated the impact of sotagliflozin, a dual SGLT1/2 inhibitor, on patients with type 2 diabetes and chronic kidney disease or heart failure.

Deepak Bhatt, MD, MPH, reflects on the rapid ascent of sotagliflozin (Zynquista) into the spotlight of clinicians specializing in cardiometabolic health thanks to the success of the phase 3 SCORED and SOLOIST trials.

Experts in endocrinology build a discussion on new intranasal and injectable formulations of glucagon and discuss their benefits compared to glucagon kits that require reconstitution.

A panel of thought leaders in the management of diabetes reviews the mainstays of treatment for hypoglycemic episodes and builds a discussion on effective non-pharmacologic strategies for raising blood glucose levels.

Using banked samples from the CANVAS trial, investigators demonstrate the ability of KidneyIntelX to monitor therapeutic response to SGLT2 inhibitors and predict disease progression in patients with type 2 diabetes and chronic kidney disease.

Data from the AMPLITUDE-O trial demonstrates the effects of the exendin-4-based GLP-1 RA efpeglenatide on cardiovascular and renal outcomes among patients with type 2 diabetes and cardiovascular disease or kidney disease.